CMC Biologics Licenses its CHEF1® Expression System to Oxford BioTherapeutics
Complete the form below to unlock access to ALL audio articles.
CMC Biologics and Oxford BioTherapeutics (OBT) have announced that they have entered into a nonexclusive license agreement providing OBT with access to CMC Biologics’ CHEF1® expression system.
The agreement, financial terms of which have not been disclosed, covers the research, development, and commercial use of the system by OBT.
CMC Biologics’ CHEF1 cell line development platform promotes high level expression of recombinant proteins early in development and allows rapid isolation of cell lines, delivering stable, production-quality cell lines in as little as 12 weeks.
The technology behind CHEF1 is proven, having been previously employed for a marketed biologic.
OBT intends to use the CHEF1 system for the efficient production of its oncologic therapeutic antibodies, each of which is directed to a novel target identified by OBT using its OGAP® proteomic database.
The license to CHEF1 signifies the continued expansion of OBT’s access to world-class antibody technologies, and demonstrates OBT’s commitment to strengthening its production and preclinical capabilities as its pipeline matures.
“We are very pleased to add CMC Biologics’ CHEF1 system to our technology portfolio. Access to the best expression systems is critical for our antibody development team, helping us accelerate production and development of our most promising anticancer agents,” commented Tom Boone, who recently joined OBT as Senior Vice President, Protein Sciences, following 28 years at Amgen.
“By licensing industry-leading technologies, such as the CHEF1 system, OBT further increases its research and development capabilities in line with our strategy to advance our pipeline of therapeutic antibodies toward clinical development,” noted Jon Terrett, OBT’s Chief Scientific Officer.
“CMC Biologics is delighted to provide its CHEF1 expression system to OBT,” said Mads Laustsen, Chief Science Officer of CMC Biologics. “We believe the advantages of the CHEF1 system will help OBT generate cell lines in a highly efficient and effective way.”
